Manali Kamdar, MD

Manali Kamdar, MD, discusses the long-term efficacy findings with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Manali Kamdar, MD, discusses the rationale for optimizing monitoring after the treatment of liso-cel in patients with mantle cell lymphoma.

Manali Kamdar, MD, discusses an analysis of the timing of CRS and ICANS among patients with MCL and other hematologic malignancies treated with liso-cel.

Manali Kamdar, MD, discusses evolving treatment paradigms in diffuse large B-cell lymphoma.

Manali Kamdar, MD, discusses common toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

Manali Kamdar, MD, discusses which populations of lymphoma subtypes, such as MCL, may derive the most benefit from liso-cel treatment.

Manali Kamdar, MD, discusses the patient population included in the mantle cell lymphoma cohort of the phase 3 TRANSCEND NHL 001 trial.

Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.

Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.

Experts discuss the role of clinical and real-world data in informing treatment sequencing in patients with large B-cell lymphoma (LBCL) in the academic and community setting,

Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.

Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Matthew Lunning, DO, FACP, discusses the role of CAR T-cell therapy in the second-line treatment of large B-cell lymphoma (LBCL).

Experts provide their perspective on the treatment landscape for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

In the context of CAR T-cell therapy, Manali Kamdar, MD, reviews TRANSFORM, ZUMA-7, and PILOT trials in the treatment of patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Experts discuss Large B-Cell Lymphoma (LBCL) and treatment strategies for patients with LBCL.

Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.